Volume 136, Issue 4, Pages 732-738 (October 2015) Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis Caroline Sindet-Pedersen, Jannik Langtved Pallisgaard, Jonas Bjerring Olesen, Gunnar Hilmar Gislason, Lourdes Cantarero Arevalo Thrombosis Research Volume 136, Issue 4, Pages 732-738 (October 2015) DOI: 10.1016/j.thromres.2015.07.022 Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 1 Flow chart of selection process. Thrombosis Research 2015 136, 732-738DOI: (10.1016/j.thromres.2015.07.022) Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 2 Forest plot of risk of recurrent venous thromboembolism (VTE) or death related to VTE of direct oral anticoagulants (DOACS) and warfarin compared to placebo. DOACs and warfarin significantly reduced the risk of recurrent VTE when compared to placebo, with a relative risk reduction of 83 % (CI:0.12-0.24, P<0.0001) in the DOAC and warfarin group. Thrombosis Research 2015 136, 732-738DOI: (10.1016/j.thromres.2015.07.022) Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 3 Forest plot of risk of major bleeding when direct oral anticoagulants (DOACS) and warfarin are compared to placebo. No significant increase in the risk of major bleeding was observed with a relative risk ratio of 1.15 (CI: 0.40-3.31, P=0.38). Thrombosis Research 2015 136, 732-738DOI: (10.1016/j.thromres.2015.07.022) Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 4 Forestplot of risk of NMCRB bleeding events when direct oral anticoagulants (DOACS) and warfarin are compared to placebo. A significant risk of NMCRB bleeding events was observed with a risk ratio of 2.12 (CI: 1.55-2.90, P<0.0001). Thrombosis Research 2015 136, 732-738DOI: (10.1016/j.thromres.2015.07.022) Copyright © 2015 Elsevier Ltd Terms and Conditions